Cytokinetics, Incorporated is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company announced in the following press release that, “CK-2018509 decreased the elevated mean arterial blood pressure with a minimal effect on heart rate in two animal models of hypertension, spontaneously hypertensive rats and Dahl salt-sensitive rats. “
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: https://cytokinetics.com